White Powder Sidenafil  Man Sex Enhancement Hormones Silenafil Citrate CAS: 139755-83-2

Silenafil, is a medication used to treat erectile dysfunctionandpulmonary arterial hypertension. Its effectiveness for treating  dysfunction in women has not been demonstrated.

Sidenafil relaxes muscles found in the walls of blood vessels and increases blood flow to particular areas of the body.

Sidenafil under the name  is used to treat erectile dysfunction (impotence) in men.

Another brand of sidenafil is Revatio, which is used to treat pulmonary arterial hypertension and improve exercise capacity in men and women.

Quick details:

Chemical name: Sldenafil 
CAS: 139755-83-2
Assay: 99% min.
Molecular formula: C22H30N6O4S
Molecular weight: 474.58
Packing: 1kg net/foil bag, 5kg/drum.
Delivery: Express courier.
Character: White or almost white crystalline powder, odorless, bitter astringent taste, insoluble in water and ethanol.

Usage:

1. Treating high blood pressure in the lungs (pulmonary arterial hypertension [PAH]). It may also be used for other conditions as determined by your doctor.

2. Silenafil is a phosphodiesterase type 5 (PDE5) inhibitor. It works by relaxing and dilating the blood vessels in the lungs. This lowers the blood pressure in the lungs and helps to improve your ability to exercise.

Application:

Silenafil citrate,Revatio and under various other trade names, is a drug used to treat erectile dysfunction and pulmonary arterial hypertension (PAH). It was originally discovered by Pfizer scientists Andrew Bell, David Brown, and Nicholas Terrett.

The primary indication of sidenafil is treatment of erectile dysfunction (inability to sustain a satisfactory erection to complete intercourse). Its use is now standard treatment for erectile dysfunction in all settings, including diabetes.

In clinical trials, the most common adverse effects of silenafil use included headache, flushing, dyspepsia, nasal congestion and impaired vision, including photophobia and blurred vision.Some sildenafl users have complained of seeing everything tinted blue (cyanopsia).Some complained of blurriness and loss of peripheral vision. In July 2005, the FDA found that sildnafil could lead to vision impairment in rare cases and a number of studies have linked sildnafil use with nonarteritic anterior ischemic optic neuropathy.

Rare but serious adverse effects found through postmarketing surveillance include priapism, severe hypotension, myocardial infarction (heart attack), ventricular arrhythmias, stroke, increased intraocular pressure, and sudden hearing loss. As a result of these postmarketing reports, in October 2007, the FDA announced that the labeling for all PDE5 inhibitors, including sildnafil, required a more prominent warning of the potential risk of sudden hearing loss.